Transforming DBS from reactive management to informed therapy optimization
The BrainSense™ suite of tools
The Percept™ family with BrainSense™ technology is the first sensing-enabled DBS system offering insights into a patient’s condition inside and outside of the clinic throughout the patient journey.
©2026 FIERCE. All right reserved.
©2025 TIME USA LLC. All rights reserved. Used under license.
BrainSense™ aDBS automatically adjusts the level of therapeutic stimulation based on patient neurophysiology data in real time, providing more personalized therapy compared to traditional cDBS.
The BrainSense™ Electrode Identifier feature guides you to the sensing “sweet spot” on the lead, providing a starting point for DBS programming and identification of initial contacts for stimulation delivery.‡
Empowering clinicians to tailor treatment to each patient’s symptoms.
Access on-demand resources — videos, webinars, and more — to deepen your knowledge and uncover the innovations transforming movement disorder care.
BrainSense™ technology is the sensing and intelligence platform behind the Medtronic DBS ecosystem. It captures and visualizes patient-specific brain signal data, helping clinicians make more informed programming and therapy decisions over time.
BrainSense™ provides objective data that can help clinicians identify programming starting points, evaluate therapy effectiveness, and make adjustments with greater confidence. Its suite of tools supports decision-making throughout the DBS care journey, from initial programming to ongoing optimization.
No. BrainSense™ is designed to give clinicians flexibility to start with the capabilities that fit their workflow today and expand use as their practice and patient needs evolve. The platform supports a range of experience levels and clinical approaches.
The BrainSense™ ecosystem includes sensing-enabled DBS devices, advanced programming capabilities, adaptive DBS technology for Parkinson's disease, and Electrode Identifier. Together, these tools help connect sensing data, programming insights, and patient information in one integrated approach to care.
BrainSense™ technology provides visibility into patient-specific brain signal data and therapy trends over time. By helping clinicians better understand individual patient needs, it supports more personalized and data-informed DBS care.
No. BrainSense™ technology is available exclusively with the Medtronic Percept™ family of neurostimulators. The Percept™ platform combines DBS therapy with sensing capabilities that provide access to patient-specific brain signal data and advanced tools designed to support personalized, data-informed care.
Percept™ PC neurostimulator with exclusive, adaptive BrainSense™ technology uses advanced programming capabilities for closed-loop DBS therapy.
Percept™ RC rechargeable neurostimulator with exclusive, adaptive BrainSense™ technology uses advanced programming capabilities for closed-loop DBS.
The SenSight™ directional DBS lead system combines the benefits of directionality with the power of sensing.
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on markets comply with legislation (if applicable) on medical devices. For any further information, contact your local Medtronic representative.
† The sensing feature of the Percept™ PC and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status.
‡ Improved motor symptom control results were based on post hoc analysis averaging overall patients aDBS on time results compared to cDBS. Results prestend for dual threshold aDBS. N=40. Based on results from an open-label comparison.
§ Data from 45 patients who were previously stable on cDBS (primary cohort).
◊ Over traditional DBS (cDBS) after using 30 days.
¶ The safety profile observed for aDBS is consistent with the safety profile for cDBS.
We do not review or control the content of external sites and are not responsible for any interactions or transactions that may occur there. Any product availability and regulatory requirements on the destination site may differ depending on your location. When you continue, the terms of use and privacy statement of the external site will apply.
Product availability and regulatory requirements may differ depending on your location. The destination website is governed by the laws and regulations of the country in which it operates, which may be different from those in your country. When you continue, the terms of use and privacy statement of the destination Medtronic site will apply.
